Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62nd Annual ESPE Meeting 2024
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62nd Annual ESPE Meeting 2024
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK.
得克萨斯州奥斯汀，2024年10月30日（GLOBE NEWSWIRE）——专注于罕见疾病疗法的临床阶段生物制药公司Lumos Pharma（纳斯达克股票代码：LUMO）今天宣布，对该公司2期oraGrowth210和OraGrowth212临床试验数据的最新分析已获准在第62届欧洲儿科内分泌学会年会（ESPE）上进行口头陈述 2024，将于 2024 年 11 月 16 日至 18 日在英国利物浦举行。
Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on Sunday, November 17th, by Elżbieta Petriczko, MD, PhD, Pomeranian Medical University, Szczecin, Poland, and on Monday, November 18th, by Peter E. Clayton, MD, University of Manchester, Manchester, UK, respectively.
两份评估口服Lum-201治疗儿科生长激素缺乏症（PGHD）的OraGrowth试验数据的摘要将于11月17日星期日由波兰什切青波美拉尼亚医科大学医学博士Elzbieta Petriczko和英国曼彻斯特大学医学博士彼得·克莱顿于11月18日星期一分别发表。
LUM-201 Oral Abstract Presentations:
LUM-201 口头摘要演讲：
Sunday, November 17th – Session: Free Communications 7: GH and IGFs – 10:50AM Local Time
11 月 17 日星期日 — 会议：免费交流 7：GH 和 IGF — 当地时间上午 10:50
- FC7.6 Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment (Elżbieta Petriczko, MD, PhD, et al)
- FC7.6 摘要标题为《Oragrowth210 和 Oragrowth212 在接受治疗 12 至 24 个月以上的儿科生长激素缺乏症 (PGHD) 试验中的生长、IGF-1 和 IGFBP-3 对口服 lum-201 的反应》（Elzbieta Petriczko，医学博士，博士等）
Monday, November 18th – Session: Free Communications 15: Late Breaking – 9:40AM Local Time
11 月 18 日星期一 — 会议：免费交流 15：深夜休息 — 当地时间上午 9:40
- FC15.2 Abstract entitled, Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD) (Peter E. Clayton, MD, et al)
- FC15.2 摘要标题为，口服生长激素促分泌物 Lum-201 诱导的脉动激素分泌量和模式与中度儿科生长激素缺乏 (PGHD) 的生长和 IGF-1 反应有关（医学博士 Peter E. Clayton 等）
About Lumos Pharma
关于 Lumos Phar
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma's lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit .
Lumos Pharma, Inc. 是一家临床阶段的生物制药公司，专注于罕见疾病疗法的开发和商业化。该公司成立并由一支在罕见病药物开发方面具有长期经验的管理团队领导。Lumos Pharma的主要候选疗法Lum-201是一种新型的口服生长激素（GH）促分泌剂，旨在将全球约47亿美元的生长激素市场从注射剂转变为口服疗法。LUM-201目前正在多项儿科生长激素缺乏症（PGHD）的2期临床研究中接受评估，并已获得美国和欧盟的孤儿药认定。欲了解更多信息，请访问。
Investor & Media Contact:
投资者和媒体联系人：
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
丽莎米勒
Lumos Parma 投资者关系
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
资料来源：Lumos Pharma, Inc.
